UNSPSC 51286401: Octapinol

This classification denotes an antimicrobial with the molecular formula C15H31NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4758KDH62A, chemically known as 1-piperidineethanol, 4-(2-procylpentyl)- but more generally known as octapinol, which bears US NIH Compound Identifier 68906. European Medicines Agency schedules Octapinol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09406MIG.

The term OCTAPINOL is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 34, No. 10 1980, List 20). OCTAPINOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: OCCN1CCC(CC(CCC)CCC)CC1.

UNSPSC 51286401 Octapinol is a Commodity code with minimal recent state and local activity directly aligned to the chemical product itself. The code's nominal scope does not map clearly to the recent opportunities tagged under it, which involve naloxone procurement, pharmacy benefit program design, medical and first aid supplies, and generic pharmaceuticals through cooperative purchasing — none of which represent octapinol specifically. State and local governments procuring under this code appear to be acquiring pharmaceutical products and medical supplies as part of broader health, emergency response, or pharmacy benefit initiatives rather than octapinol as a standalone chemical or ingredient.

The recent opportunities span health departments, fire departments, and statewide cooperative purchasing alliances across Florida, Texas, Minnesota, and Oregon. Seminole County, Florida issued an IFB (IFB60459723LAS, due July 26, 2023) for naloxone and drug deactivation systems for quarterly delivery to county health facilities. The City of Tampa released an ITB (26P00145, due March 13, 2026) for medical and first aid supplies including respiratory equipment and consumables for the Fire Department Rescue Division, estimated at $700,000.00 and sheltered for certified Small Local Business Enterprises with a 5 percent bid discount cap. The Texas Health and Human Services Commission posted an RFI (HHS0017013, April 3, 2026) on direct-to-manufacturer prescription programs as a market-intelligence phase preceding formal competitive solicitation. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP (S1070000015802, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed through state and local facilities in Minnesota and Oregon, with awards effective July 1, 2026. The code shows limited concrete activity mapped directly to octapinol procurement and warrants close monitoring to distinguish whether recent tagging reflects misclassification or emerging state and local demand for the substance.